X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (141) 141
female (114) 114
male (114) 114
aged (102) 102
middle aged (99) 99
heart failure (93) 93
cardiac & cardiovascular systems (89) 89
mortality (80) 80
prognosis (64) 64
cardiovascular (43) 43
aged, 80 and over (39) 39
risk factors (38) 38
myocardial infarction (36) 36
acute heart failure (35) 35
prospective studies (34) 34
hypertension (32) 32
analysis (30) 30
adult (28) 28
risk (28) 28
treatment outcome (28) 28
patients (27) 27
abridged index medicus (26) 26
cardiology (26) 26
cardiology and cardiovascular medicine (26) 26
heart attacks (25) 25
acute coronary syndrome (24) 24
heart failure - mortality (24) 24
management (24) 24
patient outcomes (24) 24
acute coronary syndromes (23) 23
acute disease (23) 23
care and treatment (23) 23
diagnosis (23) 23
guidelines (23) 23
hospitalization (23) 23
outcomes (23) 23
cardiac patients (22) 22
cardiogenic shock (21) 21
double-blind method (21) 21
atrial fibrillation (20) 20
cardiovascular disease (20) 20
medicine, general & internal (20) 20
time factors (20) 20
association (19) 19
drug therapy (19) 19
cardiovascular diseases (18) 18
diabetes (18) 18
follow-up studies (18) 18
prevention (18) 18
disease (17) 17
electrocardiography (17) 17
heart attack (17) 17
internal medicine (17) 17
blood pressure (16) 16
heart failure - physiopathology (16) 16
secondary prevention (16) 16
survival (16) 16
ticagrelor (16) 16
acute myocardial-infarction (15) 15
diabetes mellitus (15) 15
heart rate (15) 15
research (15) 15
stroke (15) 15
heart (14) 14
heart failure - drug therapy (14) 14
hemorrhage - chemically induced (14) 14
incidence (14) 14
myocardial infarction - drug therapy (14) 14
biomarkers - blood (13) 13
clinical medicine (13) 13
clinical trials (13) 13
hospital mortality (13) 13
hospitals (13) 13
medicine (13) 13
peripheral vascular disease (13) 13
predictive value of tests (13) 13
risk assessment (13) 13
chronic heart failure (12) 12
clopidogrel (12) 12
czech republic - epidemiology (12) 12
heart diseases (12) 12
heart failure - complications (12) 12
heart failure - diagnosis (12) 12
kaplan-meier estimate (12) 12
medical prognosis (12) 12
medical research (12) 12
medicine, experimental (12) 12
prevalence (12) 12
research article (12) 12
trial (12) 12
dosage and administration (11) 11
heart failure - blood (11) 11
heart-failure (11) 11
klinisk medicin (11) 11
medicine, research & experimental (11) 11
natriuretic peptides (11) 11
registries (11) 11
therapy (11) 11
aspirin (10) 10
coronary vessels (10) 10
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


CIRCULATION, ISSN 0009-7322, 07/2011, Volume 124, Issue 2, pp. F7 - F9
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 388, Issue 10055, pp. 1995 - 2003
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 388, Issue 10062, pp. 2895 - 2903
Journal Article
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2010, Volume 55, Issue 19, pp. 2118 - 2124
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 366, Issue 15, pp. 1404 - 1413
Patients with atherosclerotic vascular disease were randomly assigned to receive the thrombin antagonist vorapaxar or placebo. Vorapaxar reduced the rate of... 
ATOPAXAR | MEDICINE, GENERAL & INTERNAL | CLOPIDOGREL | EFFICACY | SAFETY | TOLERABILITY | DOUBLE-BLIND | PRASUGREL | LESSONS | ANTAGONISTS | ASPIRIN | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Risk | Secondary Prevention | Pyridines - adverse effects | Cardiovascular Diseases - mortality | Female | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Pyridines - therapeutic use | Double-Blind Method | Hemorrhage - epidemiology | Receptor, PAR-1 - antagonists & inhibitors | Kaplan-Meier Estimate | Peripheral Arterial Disease - drug therapy | Stroke - drug therapy | Lactones - adverse effects | Lactones - therapeutic use | Retreatment | Myocardial Infarction - drug therapy | Brain Ischemia - drug therapy | Intracranial Hemorrhages - chemically induced | Intracranial Hemorrhages - epidemiology | Aged | Hemorrhage - chemically induced | Prevention | Drugs | Aggregation | Dose-response relationship (Biochemistry) | Atheroembolism | Blood platelets | Atherosclerosis | Product/Service Evaluations | Dosage and administration | Drug therapy | Myocardial infarction | Cerebral infarction | Stroke | Aspirin | Heart attacks | Proteinase-activated receptor 1 | Thrombin | Hemorrhage | Patients | Bleeding | Disease prevention | Ischemia | Arteriosclerosis | Death | Cardiovascular diseases | Health risk assessment | Computer Science | Medical Imaging
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 04/2016, Volume 315, Issue 15, pp. 1591 - 1599
IMPORTANCE: p38 Mitogen-activated protein kinase (MAPK)–stimulated inflammation is implicated in atherogenesis, plaque destabilization, and maladaptive... 
APOPTOSIS | MEDICINE, GENERAL & INTERNAL | ACTIVATED PROTEIN-KINASE | INHIBITION | EVENTS | PATHWAY | HEART-FAILURE | MAPK | ACUTE CORONARY SYNDROME | Recurrence | Myocardial Infarction - mortality | Humans | Middle Aged | Male | Secondary Prevention | Cyclopropanes - adverse effects | Protein Kinase Inhibitors - adverse effects | Cyclopropanes - therapeutic use | Pyridines - adverse effects | Treatment Failure | Female | C-Reactive Protein - analysis | Myocardial Infarction - enzymology | Pyridines - therapeutic use | Double-Blind Method | Drug Administration Schedule | Myocardial Ischemia - prevention & control | Hospitalization | Myocardial Revascularization | Algorithms | Myocardial Infarction - drug therapy | Protein Kinase Inhibitors - therapeutic use | p38 Mitogen-Activated Protein Kinases - antagonists & inhibitors | Aged | Myocardial Ischemia - surgery | Clinical trials | Care and treatment | Usage | Dosage and administration | Extracellular signal-regulated kinases | Heart attack | Patient safety | Inhibitor drugs | Heart attacks | Clinical outcomes | Pyridines/adverse effects/therapeutic use | Cyclopropanes/adverse effects/therapeutic use | C-Reactive Protein/analysis | Klinisk medicin | Clinical Medicine | p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors | Myocardial Ischemia/prevention & control/surgery | Protein Kinase Inhibitors/adverse effects/therapeutic use | Myocardial Infarction/drug therapy/enzymology/mortality
Journal Article
Intensive care medicine, ISSN 1432-1238, 2018, Volume 44, Issue 6, pp. 847 - 856
Journal Article
Journal Article
Journal Article
PloS one, ISSN 1932-6203, 2019, Volume 14, Issue 3, p. e0214363
Journal Article
European heart journal, ISSN 1522-9645, 2010, Volume 31, Issue 24, pp. 3006 - 3016
Journal Article